Accellena Research and Development describes new TAAR1 agonists

Accellena Research and Development LLC has identified substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl) ethanamines acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists reported to be useful for the treatment of cardiovascular disorders, diabetes, metabolic diseases, migraine, neurological disorders, obesity, psychiatric disorders and substance abuse and dependence.

Link to original publication

Full article is available for subscribers.